Dichlorphenamide-¹³C₆

Dichlorphenamide-¹³C₆ is intended for use as an internal standard for the quantification of dichlorphenamide (Item No. 23658) by GC- or LC-MS. Dichlorphenamide is a sulfonamide and an orally bioavailable carbonic anhydrase (CA) inhibitor (K_is = 1.20, 38, 50, and 50 nM for the human CA isoforms CAI, CAII, CAIX, and CAXII, respectively).¹ It lowers intraocular pressure in rabbits when 50 µl of a 10% solution is applied topically to the eye.² Dichlorphenamide rescues the potassium deficiency and prevents insulin-induced paralysis in a rat model of familial hypokalemic periodic paralysis when administered at a dose of 5.6 mg/kg per day for ten days.³ Formulations containing dichlorphenamide have been used in the treatment of glaucoma and primary periodic paralysis.

WARNING This product is not for human or veterinary use.

1. Brzozowski, Z., Slawiǹski, J., Innocenti, A., et al. Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII. Eur. J. Med. Chem. 45(9), 3656-3661 (2010).

2. Lotti, V.J., Schmitt, C.J., and Gautheron, P.D. Topical ocular hypotensive activity and ocular penetration of dichlorphenamide sodium in rabbits. Graefes Arch. Clin. Exp. Ophthalmol. 222(1), 13-19 (1984).

3. Tricarico, D., Mele, A., and Conte Camerino, D. Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca²⁺-activated-K⁺ channels. Neuromuscul. Disord. 16(1), 39-45 (2006).